Diurnal Group PLC Replacement - Director Dealings (1523B)
06 January 2018 - 4:04AM
UK Regulatory
TIDMDNL
RNS Number : 1523B
Diurnal Group PLC
05 January 2018
The following amendments have been made to the 'Director
Dealings' announcement released on 5 January at 13.19 under RNS No
1273B.
In the PDMR dealing disclosure form, the price paid per share
should have been described as GBP0.05 rather than GBP539.55, and
the place of the transaction should have been described as Off
Market rather than London Stock Exchange, AIM. All other details
remain unchanged.
The full amended text is shown below.
5 January 2018
Diurnal Group plc
("Diurnal" or the "Company")
Replacement - Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces that Non-Executive Director, John Goddard, has
acquired 10,791 recently vested shares at GBP0.05 per share.
As published in the Company's AIM Admission Document, published
on 21 December 2015, and in connection with his recruitment, John
Goddard was awarded 32,374 ordinary shares of GBP0.05 each for
which Mr Goddard will pay the nominal value for each share. The
award of shares vest in thirds 18, 24 and 36 months from 24
December 2015, being the date of admission to AIM. There are no
other performance criteria.
John Goddard's interest in the Company is now as follows:
Name Position Total number of conditional shares Total number of ordinary shares now
now held held
-------------- ------------------------ ------------------------------------- -------------------------------------
John Goddard Non-Executive Director 10,792 37,774
-------------- ------------------------ ------------------------------------- -------------------------------------
For further information, please visit www.diurnal.co.uk
or contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive
Officer
Richard Bungay, Chief Financial
Officer
Numis Securities Ltd (Nominated +44 (0)20 7260
Adviser) 1000
Nominated Adviser: Michael Meade,
Paul Gillam, Freddie Barnfield
Corporate Broking: James Black
Panmure Gordon (UK) Limited (Joint +44 (0) 20 7886
Broker) 2500
Corporate Finance: Freddy Crossley
Corporate Broking: Tom Salvesen
+44 (0)20 3727
FTI Consulting 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company
developing high quality products for the global market for the
life-long treatment of chronic endocrine conditions, including
Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its
expertise and innovative research activities focus on
circadian-based endocrinology to yield novel product candidates in
the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
1 Details of the person discharging managerial
responsibilities / person closely associated
---- -----------------------------------------------------------------
a) Name John Goddard
---- ------------------------------ ---------------------------------
2 Reason for the notification
---- -----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------------ ---------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------------ ---------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- -----------------------------------------------------------------
a) Name Diurnal Group plc
---- ------------------------------ ---------------------------------
b) LEI 213800I2HNUNZN1LDH29
---- ------------------------------ ---------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- -----------------------------------------------------------------
a) Description of Ordinary shares of 5p each
the financial
instrument, type
of instrument
----
Identification GB00BDB6Q760
code
b) Nature of the Purchase of shares
transaction
---- ------------------------------ ---------------------------------
c) Price(s) and volume(s)
---- -------------- --------------
Price(s) Volume(s)
---- -------------- --------------
GBP0.05 10,791
-------------------------------------------------- --------------
d) Aggregated information
----
- Aggregated volume 10,791
- Price GBP539.55
e) Date of the transaction 5 January 2018
---- ------------------------------ ---------------------------------
f) Place of the transaction Off Market
---- ------------------------------ ---------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUGUPUGUPRGMA
(END) Dow Jones Newswires
January 05, 2018 12:04 ET (17:04 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024